^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1d
    Sustained disease control in ovarian carcinosarcoma treated with postoperative hyperthermic intraperitoneal chemotherapy and targeted maintenance: a case report. (PubMed, Front Med (Lausanne))
    After cytoreductive surgery, she received postoperative HIPEC followed by adjuvant chemotherapy nab-paclitaxel and carboplatin, then sequential maintenance therapy with bevacizumab followed by olaparib based on homologous recombination deficiency (HRD) positivity. The patient remained progression-free with good performance status at 24 months of follow-up. This hypothesis-generating case suggests that for selected patients with OCS, a multimodal approach incorporating aggressive cytoreductive surgery, postoperative HIPEC, and HRD-guided sequential maintenance therapy may warrant further investigation.
    Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • albumin-bound paclitaxel
    1d
    GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov)
    P2, N=176, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    gemcitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
    1d
    BGB-A317-15025-101: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=157, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • BGB-15025
    1d
    AURORAS-1: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=600, Recruiting, Erasca, Inc. | N=200 --> 600
    Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab) • gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel
    3d
    An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies (clinicaltrials.gov)
    P2, N=30, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    3d
    SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2/3, N=30, Recruiting, Second Affiliated Hospital of Nanchang University | Trial completion date: Apr 2026 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    3d
    Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. (PubMed, Clin Cancer Res)
    NIS793 effectively inhibited TGFβ signaling and led to stroma remodeling but failed to improve outcomes in metastatic PDAC. These findings highlight the complexity of TGFβ biology and caution against its blockade in combination with chemotherapy for PDAC. Future strategies should consider context-dependent effects of TGFβ inhibition(NCT04390763).
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    gemcitabine • albumin-bound paclitaxel • spartalizumab (PDR001) • nisevokitug (NIS793)
    4d
    Electro-Acupuncture in Lung cancER : EALER Study (clinicaltrials.gov)
    P=N/A, N=424, Recruiting, Guangzhou University of Traditional Chinese Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • albumin-bound paclitaxel
    4d
    Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel. (PubMed, Cancer)
    In patients with very high-risk NMIBC, magnetic resonance imaging-derived radiomic phenotypes can be used to stratify responses to immunochemotherapy and capture functional immune states. Noninvasive radiomic profiling may guide precision treatment selection in patients who are unfit for radical cystectomy, and prospective validation is warranted before clinical adoption.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    4d
    SONIC: Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=67, Not yet recruiting, University Health Network, Toronto
    New P1/2 trial
    |
    PurIST℠ Test
    |
    gemcitabine • albumin-bound paclitaxel • samuraciclib (CT7001)
    4d
    POD1UM-304: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=583, Completed, Incyte Corporation | Trial completion date: Aug 2026 --> May 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Zynyz (retifanlimab-dlwr)
    5d
    The Seven Trial: Exploiting the Unfolded Protein Response (clinicaltrials.gov)
    P1, N=6, Terminated, HonorHealth Research Institute | Trial completion date: Dec 2026 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; The study was terminated early per the recommendation of the Data and Safety Monitoring Board (DSMB) after a planned interim analysis met pre-specified criteria for futility.
    Trial completion date • Trial termination • Trial primary completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • celecoxib oral • chloroquine phosphate